Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
14.47
-0.18 (-1.23%)
Sep 4, 2026, 3:08 PM EDT - Market open
Corvus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 |
Selling, General & Admin | 3.33 | 3.7 | 2.28 | 2.12 | 2.39 | 2.47 | 2.13 | 2.03 | 1.82 | 2.18 | 1.63 | 1.6 | 1.65 | 1.92 | 1.44 | 1.96 | 1.94 | 2.17 | 1.88 | 1.96 |
Research & Development | 15.96 | 11.18 | 9.94 | 8.45 | 7.87 | 7.45 | 5.97 | 5.22 | 4.11 | 4.08 | 4 | 3.97 | 3.97 | 4.59 | 4.08 | 10.37 | 4.92 | 5.1 | 4.79 | 6.99 |
Operating Expenses | 19.3 | 14.88 | 12.22 | 10.57 | 10.26 | 9.92 | 8.11 | 7.26 | 5.94 | 6.25 | 5.63 | 5.56 | 5.62 | 6.52 | 5.52 | 12.33 | 6.87 | 7.27 | 6.67 | 8.95 |
Operating Income | -19.3 | -14.88 | -12.22 | -10.57 | -10.26 | -9.92 | -8.11 | -7.26 | -5.94 | -6.25 | -5.63 | -5.56 | -5.62 | -6.52 | -5.52 | -12.33 | -6.87 | -7.27 | -6.67 | -8.95 |
Interest & Investment Income | 2.05 | 1.78 | 0.6 | 0.74 | 0.64 | 0.53 | 0.51 | 0.57 | 0.43 | 0.32 | 0.38 | 0.43 | 0.4 | 0.38 | 0.32 | 0.23 | 0.1 | 0.01 | - | - |
Earnings From Equity Investments | -0.71 | -0.6 | -0.71 | -0.32 | -0.39 | -0.54 | -2.17 | -0.68 | -0.58 | 0.24 | -1.4 | -0.87 | -1.28 | -1.73 | -4.64 | -2.73 | -1.6 | -1.04 | -2.56 | -1.71 |
Other Non Operating Income (Expenses) | - | - | - | - | 2.01 | 25.13 | -2.35 | -32.85 | 1.82 | - | - | - | - | - | - | - | - | - | -0.01 | -0.01 |
EBT Excluding Unusual Items | -17.96 | -13.69 | -12.32 | -10.16 | -8 | 15.19 | -12.12 | -40.22 | -4.26 | -5.7 | -6.65 | -6 | -6.5 | -7.87 | -9.84 | -14.83 | -8.36 | -8.3 | -9.24 | -10.67 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | - | 0.01 | - | - | - | - | - | - | - | 0.02 | - | - | - | - | - |
Pretax Income | -17.96 | -13.69 | -12.32 | -10.16 | -8 | 15.19 | -12.11 | -40.22 | -4.26 | -5.7 | -6.65 | -6 | -6.5 | -7.87 | -9.82 | -14.83 | -8.36 | -8.3 | -9.24 | -10.67 |
Net Income | -17.96 | -13.69 | -12.32 | -10.16 | -8 | 15.19 | -12.11 | -40.22 | -4.26 | -5.7 | -6.65 | -6 | -6.5 | -7.87 | -9.82 | -14.83 | -8.36 | -8.3 | -9.24 | -10.67 |
Net Income to Common | -17.96 | -13.69 | -12.32 | -10.16 | -8 | 15.19 | -12.11 | -40.22 | -4.26 | -5.7 | -6.65 | -6 | -6.5 | -7.87 | -9.82 | -14.83 | -8.36 | -8.3 | -9.24 | -10.67 |
Net Income Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding (Basic) | 92 | 90 | 83 | 83 | 78 | 72 | 68 | 67 | 60 | 49 | 49 | 49 | 47 | 47 | 47 | 47 | 47 | 47 | 47 | 44 |
Shares Outstanding (Diluted) | 92 | 90 | 83 | 83 | 78 | 75 | 68 | 67 | 60 | 49 | 49 | 49 | 47 | 47 | 47 | 47 | 47 | 47 | 47 | 44 |
Shares Change (YoY) | 18.76% | 19.75% | 21.38% | 24.19% | 30.25% | 53.25% | 39.37% | 36.20% | 25.71% | 5.33% | 5.34% | 5.19% | 2.03% | 0.01% | 0.00% | 5.93% | 10.19% | 34.88% | 57.41% | 48.97% |
EPS (Basic) | -0.19 | -0.15 | -0.15 | -0.12 | -0.10 | 0.21 | -0.18 | -0.60 | -0.07 | -0.12 | -0.14 | -0.12 | -0.14 | -0.17 | -0.21 | -0.32 | -0.18 | -0.18 | -0.20 | -0.24 |
EPS (Diluted) | -0.19 | -0.15 | -0.15 | -0.12 | -0.10 | -0.13 | -0.18 | -0.60 | -0.07 | -0.12 | -0.14 | -0.12 | -0.14 | -0.17 | -0.21 | -0.32 | -0.18 | -0.18 | -0.20 | -0.24 |
EPS Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Additional Metrics
Fiscal Quarter | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 |
Free Cash Flow | -15.98 | -10.47 | -9.22 | -9.57 | -5.89 | -8.3 | -8.47 | -6.32 | -5.48 | -5.16 | -5.17 | -5.43 | -5.22 | -8.15 | -7.55 | -7.19 | -6.13 | -6.42 | -6.86 | -8.43 |
Free Cash Flow Per Share | -0.17 | -0.12 | -0.11 | -0.12 | -0.08 | -0.11 | -0.12 | -0.10 | -0.09 | -0.10 | -0.10 | -0.11 | -0.11 | -0.17 | -0.16 | -0.15 | -0.13 | -0.14 | -0.15 | -0.19 |
EBITDA | -19.26 | -14.85 | -12.19 | -10.54 | -10.23 | -9.9 | -8.09 | -7.23 | -5.91 | -6.23 | -5.6 | -5.53 | -5.59 | -6.46 | -5.42 | -12.23 | -6.78 | -7.18 | -6.58 | -8.85 |
D&A For EBITDA | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.06 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.11 |
EBIT | -19.3 | -14.88 | -12.22 | -10.57 | -10.26 | -9.92 | -8.11 | -7.26 | -5.94 | -6.25 | -5.63 | -5.56 | -5.62 | -6.52 | -5.52 | -12.33 | -6.87 | -7.27 | -6.67 | -8.95 |